Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 2

Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems

Authors Randi J Hagerman, Deborah A Hall, Sarah Coffey, Maureen Leehey, James Bourgeois, et al

Published Date June 2008 Volume 2008:3(2) Pages 251—262

DOI http://dx.doi.org/10.2147/CIA.S1794

Published 30 June 2008

Randi J Hagerman1,2, Deborah A Hall3, Sarah Coffey1,2, Maureen Leehey3, James Bourgeois4, John Gould5, Lin Zhang6, Andreea Seritan4, Elizabeth Berry-Kravis7–9, John Olichney6, Joshua W Miller10, Amy L Fong11, Randall Carpenter12, Cathy Bodine13, Louise W Gane1,2, Edgar Rainin1, Hillary Hagerman1, Paul J Hagerman14

1M.I.N.D. Institute, 2Department of Pediatrics, 4Department of Psychiatry & Behavioral Sciences, 5Department of Urology, 6Department of Neurology, 10Department of Pathology and Laboratory Medicine, 14Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, CA, USA; 3Department of Neurology, University of Colorado, Denver, CO, USA; 7Department of Pediatrics, Neurology, and Biochemistry, 8Department of Neurological Sciences, 9Department of Biochemistry, Rush University Medical Center, Chicago, IL, USA; 11Physical Edge, Inc., Davis, CA, USA; 12Seaside Therapeutics, Cambridge, MA, USA; 13Department of Physical Medicine and Rehabilitation, University of Colorado Health Sciences Center, Denver, CO, USA

Abstract: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive neurological disorder that affects older adult carriers, predominantly males, of premutation alleles (55 to 200 CGG repeats) of the fragile X (FMR1) gene. Principal features of FXTAS are intention tremor, ataxia, parkinsonism, cognitive decline, and peripheral neuropathy; ancillary features include, autonomic dysfunction, and psychiatric symptoms of anxiety, depression, and disinhibition. Although controlled trials have not been carried out in individuals with FXTAS, there is a significant amount of anecdotal information regarding various treatment modalities. Moreover, there exists a great deal of evidence regarding the efficacy of various medications for treatment of other disorders (eg, Alzheimer disease) that have substantial phenotypic overlap with FXTAS. The current review summarizes what is currently known regarding the symptomatic treatment, or potential for treatment, of FXTAS.

Keywords: fragile X syndrome, dementia, ataxia, neurodegeneration, parkinsonism, tremor

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Modulation of the GABAergic pathway for the treatment of fragile X syndrome

Lozano R, Hare EB, Hagerman RJ

Neuropsychiatric Disease and Treatment 2014, 10:1769-1779

Published Date: 16 September 2014

Readers of this article also read:

Enhanced antitumor activity of realgar mediated by milling it to nanosize

Tian Y, Wang XB, Xi RG, Pan WS, Jiang S, Li Z, Zhao Y, Gao GH, Liu D

International Journal of Nanomedicine 2014, 9:745-757

Published Date: 31 January 2014

Enhancement of immunogenicity and efficacy of a plasmid DNA rabies vaccine by nanoformulation with a fourth-generation amine-terminated poly(ether imine) dendrimer

Ullas PT, Madhusudana SN, Desai A, Sagar BKC, Jayamurugan G, Rajesh YBRD, Jayaraman N

International Journal of Nanomedicine 2014, 9:627-634

Published Date: 28 January 2014

Response to vitamin D and depression in geriatric primary care patients

Muc-Wierzgoń M, Nowakowska-Zajdel E, Klakla K, Dzięgielewska-Gęsiak S, Fatyga E, Kokot T

Clinical Interventions in Aging 2013, 8:825-827

Published Date: 3 July 2013

Comparison of maximal muscle strength of elbow flexors and knee extensors between younger and older men with the same level of daily activity

Nogueira FR, Libardi CA, Vechin FC, Lixandrão ME, Berton RP, de Souza TM, Conceição MS, Cavaglieri CR, Chacon-Mikahil MP

Clinical Interventions in Aging 2013, 8:401-407

Published Date: 12 April 2013

In vitro evaluation of the effects of graphene platelets on glioblastoma multiforme cells

Jaworski S, Sawosz E, Grodzik M, Winnicka A, Prasek M, Wierzbicki M, Chwalibog A

International Journal of Nanomedicine 2013, 8:413-420

Published Date: 24 January 2013

The potential benefit of stem cell therapy after stroke: an update

Banerjee S, Williamson DA, Habib N, Chataway J

Vascular Health and Risk Management 2012, 8:569-580

Published Date: 10 October 2012

Propaedeutic study for the delivery of nucleic acid-based molecules from PLGA microparticles and stearic acid nanoparticles

G Grassi, N Coceani, R Farra, B Dapas, G Racchi, et al

International Journal of Nanomedicine 2006, 1:523-533

Published Date: 8 May 2006